Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Arvinas's EPS for the twelve months ending Jun 30, 2026 was $0.16. For fiscal 2025 it was -$1.14. The highest annual figure on record is -$1.14 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.14 | – |
| FY2024 | Dec 31, 2024 | -$2.77 | – |
| FY2023 | Dec 31, 2023 | -$6.62 | – |
| FY2022 | Dec 31, 2022 | -$5.31 | – |
| FY2021 | Dec 31, 2021 | -$3.82 | – |
| FY2020 | Dec 31, 2020 | -$3.02 | – |
| FY2019 | Dec 31, 2019 | -$2.13 | – |
| FY2018 | Dec 31, 2018 | -$25.45 | – |
| FY2017 | Dec 31, 2017 | -$15.08 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.58 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.90 | -178.9% |
| Q4 FY2025 | Dec 31, 2025 | -$1.04 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.48 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.84 | – |
| Q1 FY2025 | Mar 31, 2025 | $1.14 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.63 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.68 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.49 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.97 | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.53 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.18 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.25 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.54 | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.55 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.24 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.32 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.20 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.01 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.94 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.03 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.84 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.00 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.79 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.65 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.56 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.56 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.54 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.55 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.46 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.52 | – |
| Q3 FY2018 | Sep 30, 2018 | -$62.38 | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.96 | – |
| Q1 FY2018 | Mar 31, 2018 | -$39.86 | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.90 | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.37 | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.52 | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.29 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?